Experimental Ebola Vaccine Safe, Elicits Immune Response, Researchers Say

Agence France-Presse: Ebola vaccine is safe, researchers say
“Preliminary results from a clinical trial on an experimental Ebola vaccine developed by GlaxoSmithKline and the U.S. National Institutes of Health suggest it is safe for use, researchers said Wednesday…” (1/28).

Press Association/The Guardian: Cautious optimism follows results from trials of early Ebola vaccine
“…Although the primary goal of the trial was to assess safety, scientists also measured immune responses to Ebola seen in the participants. The vaccine was found to generate immunity with levels of antibodies increasing over a period of 28 days. But independent experts said it did not perform as well as they would have liked…” (1/28).

Reuters: Trial finds GSK Ebola shot is safe and provokes immune response
“…The data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year…” (Kelland, 1/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.